Lam, E. T., Eckhardt, S. G., Messersmith, W., Jimeno, A., O’Bryant, C. L., Ramanathan, R. K., . . . Von Hoff, D. (2017). Phase 1 study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors. Mol Cancer Ther.
Trích dẫn kiểu ChicagoLam, Elaine T., et al. "Phase 1 Study of Enavatuzumab, a First-in-class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients With Advanced Solid Tumors." Mol Cancer Ther 2017.
Trích dẫn MLALam, Elaine T., et al. "Phase 1 Study of Enavatuzumab, a First-in-class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients With Advanced Solid Tumors." Mol Cancer Ther 2017.
Cảnh báo: Các trích dẫn này có thể không phải lúc nào cũng chính xác 100%.